Regeneron Pharmaceuticals (REGN) Financials

$571.06 +16.88 (+3.05%)

As of 04/14/2025 04:00 PM Eastern

Annual Income Statements for Regeneron Pharmaceuticals

This table shows Regeneron Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	636	896	1,199	2,444	2,116	3,513	8,075	4,338	3,954	4,413
Consolidated Net Income / (Loss)	636	896	1,199	2,444	2,116	3,513	8,075	4,338	3,954	4,413
Net Income / (Loss) Continuing Operations	636	896	1,199	2,444	2,116	3,513	8,075	4,338	3,954	4,413
Total Pre-Tax Income	1,225	1,330	2,079	2,554	2,429	3,810	9,326	4,859	4,199	4,780
Total Operating Income	1,252	1,331	2,080	2,534	2,210	3,577	8,947	4,739	4,047	3,991
Total Gross Profit	3,711	4,561	5,475	4,728	5,793	7,377	13,634	10,613	11,301	12,232
Total Revenue	4,104	4,860	5,872	5,146	6,558	8,497	16,072	12,173	13,117	14,202
Operating Revenue	4,029	4,860	5,872	5,146	6,558	8,497	16,072	12,173	13,117	14,202
Total Cost of Revenue	393	300	397	418	765	1,120	2,438	1,560	1,816	1,971
Operating Cost of Revenue	393	300	397	418	765	1,120	2,438	1,560	1,816	1,971
Total Operating Expenses	2,459	3,230	3,396	2,194	3,583	3,801	4,687	5,874	7,254	8,241
Selling, General & Admin Expense	839	1,178	1,320	1,127	1,342	1,346	1,825	2,116	2,631	2,954
Research & Development Expense	1,621	2,052	2,075	1,469	2,450	2,735	2,908	3,848	4,625	5,233
Other Operating Expenses / (Income)	-	-	-	-402	-209	-280	-46	-90	-2.10	53
Total Other Income / (Expense), net	-27	-1.80	-1.10	19	219	234	379	120	152	789
Interest Expense	-	7.20	25	28	30	57	57	59	73	55
Other Income / (Expense), net	-13	5.40	24	47	250	291	436	179	225	844
Income Tax Expense	589	434	880	109	313	297	1,251	520	246	367
Basic Earnings per Share	$6.17	$8.55	$11.27	$22.65	$19.38	$32.65	$76.40	$40.51	$37.05	$40.90
Weighted Average Basic Shares Outstanding	103.06M	104.70M	106.30M	107.90M	109.20M	107.60M	105.70M	107.10M	106.70M	107.90M
Diluted Earnings per Share	$5.52	$7.70	$10.34	$21.29	$18.46	$30.52	$71.97	$38.22	$34.77	$38.34
Weighted Average Diluted Shares Outstanding	115.23M	116.30M	115.90M	114.80M	114.60M	115.10M	112.20M	113.50M	113.70M	115.10M
Weighted Average Basic & Diluted Shares Outstanding	103.10M	104.70M	106.30M	109.28M	110.02M	107.13M	108.54M	109.33M	109.76M	109.32M

This table shows Regeneron Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	1,316	1,197	818	968	1,008	1,160	722	1,432	1,341	918
Consolidated Net Income / (Loss)	1,316	1,197	818	968	1,008	1,160	722	1,432	1,341	918
Net Income / (Loss) Continuing Operations	1,316	1,197	818	968	1,008	1,160	722	1,432	1,341	918
Total Pre-Tax Income	1,510	1,325	858	1,083	1,111	1,148	701	1,628	1,493	958
Total Operating Income	1,224	1,147	947	1,017	1,111	973	751	1,070	1,180	990
Total Gross Profit	2,618	2,874	2,705	2,753	2,926	2,917	2,711	3,067	3,230	3,224
Total Revenue	2,936	3,414	3,162	3,158	3,363	3,434	3,145	3,547	3,721	3,789
Operating Revenue	2,936	3,414	3,162	3,158	3,363	3,434	3,145	3,547	3,721	3,789
Total Cost of Revenue	318	541	458	405	436	517	434	480	491	565
Operating Cost of Revenue	318	541	458	405	436	517	434	480	491	565
Total Operating Expenses	1,395	1,727	1,758	1,737	1,815	1,944	1,960	1,997	2,050	2,234
Selling, General & Admin Expense	529	661	601	652	641	738	689	759	714	792
Research & Development Expense	911	1,073	1,157	1,085	1,175	1,207	1,256	1,224	1,328	1,426
Other Operating Expenses / (Income)	-46	-6.60	-0.50	-0.60	-0.50	-0.50	15	15	8.00	16
Total Other Income / (Expense), net	286	178	-89	66	-0.20	175	-51	559	314	-32
Interest Expense	15	17	18	19	18	18	16	15	14	11
Other Income / (Expense), net	301	195	-71	85	18	193	-35	573	327	-22
Income Tax Expense	194	128	40	115	103	-12	-21	196	152	40
Basic Earnings per Share	$12.31	$11.18	$7.64	$9.05	$9.48	$10.88	$6.70	$13.25	$12.40	$8.55
Weighted Average Basic Shares Outstanding	106.90M	107.10M	107.10M	107M	106.30M	106.70M	107.80M	108.10M	108.10M	107.90M
Diluted Earnings per Share	$11.66	$10.48	$7.17	$8.50	$8.89	$10.21	$6.27	$12.41	$11.54	$8.12
Weighted Average Diluted Shares Outstanding	112.80M	113.50M	114M	113.90M	113.40M	113.70M	115.10M	115.40M	116.20M	115.10M
Weighted Average Basic & Diluted Shares Outstanding	108.90M	109.33M	109.71M	108.56M	108.95M	109.76M	110.19M	110.23M	109.89M	109.32M

This table details how cash moves in and out of Regeneron Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	160	-261	278	655	150	577	691	221	-382	-249
Net Cash From Operating Activities	1,331	1,486	1,307	2,195	2,430	2,618	7,081	5,015	4,594	4,421
Net Cash From Continuing Operating Activities	1,331	1,486	1,307	2,195	2,430	2,618	7,081	5,015	4,594	4,421
Net Income / (Loss) Continuing Operations	636	896	1,199	2,444	2,116	3,513	8,075	4,338	3,954	4,413
Consolidated Net Income / (Loss)	636	896	1,199	2,444	2,116	3,513	8,075	4,338	3,954	4,413
Depreciation Expense	75	105	146	148	210	236	286	341	421	483
Non-Cash Adjustments To Reconcile Net Income	512	605	571	440	435	297	783	1,325	1,151	901
Changes in Operating Assets and Liabilities, net	108	-119	-608	-837	-331	-1,428	-2,064	-990	-932	-1,376
Net Cash From Investing Activities	-908	-1,047	-1,005	-1,463	-2,028	-71	-5,385	-3,785	-3,185	-2,468
Net Cash From Continuing Investing Activities	-908	-1,047	-1,005	-1,463	-2,028	-71	-5,385	-3,785	-3,185	-2,468
Purchase of Property, Plant & Equipment	-678	-512	-273	-383	-430	-615	-552	-590	-719	-756
Acquisitions	-	-	-	-	-	0.00	0.00	-230	-55	-17
Purchase of Investments	-557	-809	-1,277	-1,846	-3,202	-3,241	-7,048	-7,488	-11,646	-16,617
Sale of Property, Plant & Equipment	-	-	-	-	-	-	-	0.00	0.00	20
Sale and/or Maturity of Investments	327	275	545	776	1,604	3,785	2,215	5,551	9,442	15,027
Other Investing Activities, net	-	0.00	0.00	-10	-	0.00	0.00	-1,027	-208	-126
Net Cash From Financing Activities	-263	-701	-24	-77	-252	-1,971	-1,006	-1,009	-1,790	-2,201
Net Cash From Continuing Financing Activities	-263	-701	-24	-77	-252	-1,971	-1,006	-1,009	-1,790	-2,201
Repayment of Debt	-168	-46	-20	0.00	0.00	-1,500	-	0.00	0.00	-33
Repurchase of Common Equity	-573	-643	0.00	-4.40	-276	-5,847	-1,645	-2,083	-2,235	-2,603
Issuance of Common Equity	206	127	240	115	212	2,575	1,672	1,520	1,146	1,465
Other Financing Activities, net	245	-143	-302	-187	-188	-681	-1,033	-446	-701	-1,029
Effect of Exchange Rate Changes	-	-	-	-	-	-	0.00	0.00	-0.40	-0.70
Cash Interest Paid	11	5.50	19	22	25	23	56	54	73	53
Cash Income Taxes Paid	276	481	755	206	342	188	1,218	1,502	870	743

This table details how cash moves in and out of Regeneron Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	96	-385	809	-1,979	211	578	-128	-682	84	477
Net Cash From Operating Activities	629	1,720	1,368	1,022	1,114	1,090	1,513	354	1,291	1,263
Net Cash From Continuing Operating Activities	629	1,720	1,368	1,022	1,114	1,090	1,513	354	1,291	1,263
Net Income / (Loss) Continuing Operations	1,316	1,197	818	968	1,008	1,160	722	1,432	1,341	918
Consolidated Net Income / (Loss)	1,316	1,197	818	968	1,008	1,160	722	1,432	1,341	918
Depreciation Expense	93	100	100	103	105	113	114	121	122	126
Non-Cash Adjustments To Reconcile Net Income	-27	320	426	242	319	165	426	-172	61	585
Changes in Operating Assets and Liabilities, net	-753	102	24	-291	-318	-348	250	-1,027	-233	-367
Net Cash From Investing Activities	192	-1,858	-236	-2,387	-496	-66	-1,687	-557	-574	351
Net Cash From Continuing Investing Activities	192	-1,858	-236	-2,387	-496	-66	-1,687	-557	-574	351
Purchase of Property, Plant & Equipment	-143	-152	-178	-113	-176	-251	-134	-181	-242	-200
Acquisitions	-	-	-	-	-51	-3.80	-	-	-	-12
Purchase of Investments	-570	-3,143	-1,749	-4,522	-3,243	-2,132	-5,658	-4,416	-4,591	-1,953
Sale and/or Maturity of Investments	1,832	1,537	1,793	2,269	2,998	2,383	4,132	4,055	4,259	2,582
Other Investing Activities, net	-927	-100	-101	-21	-24	-62	-28	-30	-	-67
Net Cash From Financing Activities	-725	-248	-323	-614	-407	-446	47	-478	-634	-1,136
Net Cash From Continuing Financing Activities	-725	-248	-323	-614	-407	-446	47	-478	-634	-1,136
Repurchase of Common Equity	-935	-431	-711	-689	-547	-289	-291	-604	-735	-973
Issuance of Common Equity	319	373	485	91	269	301	682	438	255	91
Other Financing Activities, net	-109	-189	-97	-16	-129	-458	-344	-312	-120	-253
Effect of Exchange Rate Changes	-	-	0.00	-0.40	-0.20	0.20	-0.50	-0.30	0.80	-0.70

This table presents Regeneron Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	5,609	6,973	8,764	11,735	14,805	17,163	25,435	29,215	33,080	37,759
Total Current Assets	2,915	3,180	4,335	6,448	7,689	9,779	14,015	15,884	19,479	18,661
Cash & Equivalents	809	535	813	1,468	1,618	2,194	2,886	3,106	2,730	2,488
Short-Term Investments	236	503	597	1,342	1,597	1,393	2,809	4,636	8,115	6,524
Accounts Receivable	1,468	1,612	1,974	2,243	2,786	4,115	6,037	5,329	5,667	6,212
Inventories, net	239	399	726	1,151	1,416	1,917	1,951	2,402	2,581	3,087
Prepaid Expenses	164	131	225	243	274	161	332	411	387	349
Plant, Property, & Equipment, net	1,594	2,083	2,359	2,576	0.00	0.00	3,482	3,763	4,146	4,600
Total Noncurrent Assets	1,100	1,710	2,071	2,711	7,116	7,384	7,938	9,567	9,455	14,499
Long-Term Investments	632	864	1,487	1,755	3,257	3,136	6,838	6,592	5,397	8,900
Intangible Assets	-	-	-	-	-	-	6.70	916	1,039	1,149
Noncurrent Deferred & Refundable Income Taxes	462	825	506	829	824	859	877	1,724	2,575	3,314
Other Noncurrent Operating Assets	5.81	20	78	127	3,035	3,390	216	336	444	1,136
Total Liabilities & Shareholders' Equity	5,609	6,973	8,764	11,735	14,805	17,163	25,435	29,215	33,080	37,759
Total Liabilities	1,954	2,524	2,620	2,977	3,716	6,138	6,666	6,551	7,107	8,406
Total Current Liabilities	811	1,241	1,136	1,443	2,097	2,697	3,933	3,141	3,423	3,944
Accounts Payable	644	879	178	218	418	476	564	589	607	790
Accrued Expenses	-	-	637	772	1,211	1,644	2,207	2,074	2,358	2,527
Current Deferred Revenue	153	232	320	453	382	578	442	478	459	628
Total Noncurrent Liabilities	1,143	1,283	1,485	1,534	1,619	3,441	2,734	3,409	3,684	4,462
Long-Term Debt	-	-	-	-	0.00	1,979	1,980	1,981	1,983	1,984
Capital Lease Obligations	363	352	704	709	714	717	-	720	720	720
Noncurrent Deferred Revenue	665	831	629	464	105	58	73	70	127	186
Other Noncurrent Operating Liabilities	116	100	152	362	800	687	680	638	854	1,571
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	3,655	4,449	6,144	8,757	11,090	11,025	18,769	22,664	25,973	29,354
Total Preferred & Common Equity	3,655	4,449	6,144	8,757	11,090	11,025	18,769	22,664	25,973	29,354
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	3,655	4,449	6,144	8,757	11,090	11,025	18,769	22,664	25,973	29,354
Common Stock	3,100	3,030	3,513	3,912	4,429	6,716	8,088	9,949	11,354	12,856
Retained Earnings	853	1,748	2,947	5,254	7,380	10,893	18,968	23,307	27,260	31,673
Treasury Stock	-306	-316	-316	-396	-740	-6,613	-8,261	-10,353	-12,560	-15,167
Accumulated Other Comprehensive Income / (Loss)	8.57	-13	0.60	-12	21	29	-26	-239	-81	-7.90

This table presents Regeneron Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Total Assets	27,678	29,215	30,060	30,658	32,163	33,080	34,370	36,087	37,442	37,759
Total Current Assets	15,429	15,884	16,909	16,923	18,635	19,479	18,872	19,082	19,334	18,661
Cash & Equivalents	3,491	3,106	3,916	1,937	2,152	2,730	2,602	1,921	2,012	2,488
Short-Term Investments	3,530	4,636	5,043	6,991	7,761	8,115	7,918	7,888	7,785	6,524
Accounts Receivable	5,548	5,329	5,119	5,121	5,585	5,667	5,222	5,717	6,107	6,212
Inventories, net	2,412	2,402	2,425	2,508	2,562	2,581	2,715	2,874	3,018	3,087
Prepaid Expenses	446	411	406	366	575	387	415	682	412	349
Plant, Property, & Equipment, net	3,704	3,763	3,881	3,923	4,006	4,146	4,226	4,306	4,439	4,600
Total Noncurrent Assets	8,545	9,567	9,270	9,812	9,522	9,455	11,273	12,699	13,669	14,499
Long-Term Investments	5,969	6,592	6,067	6,327	5,779	5,397	6,979	7,722	8,491	8,900
Intangible Assets	804	916	929	953	1,017	1,039	1,059	1,102	1,120	1,149
Noncurrent Deferred & Refundable Income Taxes	1,452	1,724	1,925	2,139	2,317	2,575	2,765	2,881	3,015	3,314
Other Noncurrent Operating Assets	320	336	350	393	410	444	470	994	1,043	1,136
Total Liabilities & Shareholders' Equity	27,678	29,215	30,060	30,658	32,163	33,080	34,370	36,087	37,442	37,759
Total Liabilities	6,239	6,551	6,565	6,640	7,259	7,107	7,379	7,881	8,116	8,406
Total Current Liabilities	2,879	3,141	3,100	3,104	3,599	3,423	3,581	3,509	3,661	3,944
Accounts Payable	536	589	600	547	537	607	671	562	497	790
Accrued Expenses	1,796	2,074	2,074	2,176	2,645	2,358	2,393	2,361	2,537	2,527
Current Deferred Revenue	547	478	426	381	417	459	517	586	627	628
Total Noncurrent Liabilities	3,360	3,409	3,465	3,535	3,660	3,684	3,798	4,372	4,455	4,462
Long-Term Debt	1,981	1,981	1,982	1,982	1,983	1,983	1,983	1,984	1,984	1,984
Capital Lease Obligations	720	720	720	720	720	720	720	720	720	720
Noncurrent Deferred Revenue	60	70	86	116	125	127	186	206	207	186
Other Noncurrent Operating Liabilities	599	638	677	717	832	854	909	1,463	1,544	1,571
Commitments & Contingencies	-	0.00	-	-	-	0.00	-	-	-	0.00
Total Equity & Noncontrolling Interests	21,439	22,664	23,495	24,018	24,904	25,973	26,991	28,206	29,326	29,354
Total Preferred & Common Equity	21,439	22,664	23,495	24,018	24,904	25,973	26,991	28,206	29,326	29,354
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	21,439	22,664	23,495	24,018	24,904	25,973	26,991	28,206	29,326	29,354
Common Stock	9,518	9,949	10,598	10,889	11,252	11,354	11,943	12,317	12,703	12,856
Retained Earnings	22,110	23,307	24,125	25,093	26,101	27,260	27,982	29,415	30,755	31,673
Treasury Stock	-9,914	-10,353	-11,046	-11,766	-12,271	-12,560	-12,857	-13,456	-14,192	-15,167
Accumulated Other Comprehensive Income / (Loss)	-275	-239	-182	-198	-177	-81	-77	-70	60	-7.90

This table displays calculated financial ratios and metrics derived from Regeneron Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	45.55%	18.44%	20.82%	-12.37%	27.44%	29.58%	89.14%	-24.26%	7.76%	8.27%
EBITDA Growth	54.38%	9.63%	56.10%	21.38%	-2.21%	53.70%	135.65%	-45.61%	-10.77%	13.31%
EBIT Growth	55.19%	7.81%	57.44%	22.73%	-4.74%	57.25%	142.63%	-47.58%	-13.13%	13.17%
NOPAT Growth	77.61%	37.87%	33.82%	102.32%	-20.66%	71.32%	134.93%	-45.38%	-9.95%	-3.31%
Net Income Growth	88.11%	40.79%	33.84%	103.95%	-13.44%	66.05%	129.86%	-46.28%	-8.87%	11.61%
EPS Growth	85.23%	39.49%	34.29%	105.90%	-13.29%	65.33%	135.81%	-46.89%	-9.03%	10.27%
Operating Cash Flow Growth	76.86%	11.66%	-12.03%	67.94%	10.70%	7.74%	170.47%	-29.18%	-8.39%	-3.78%
Free Cash Flow Firm Growth	-147.11%	585.45%	31.53%	437.10%	1.11%	9.28%	300.15%	-78.31%	69.96%	-18.01%
Invested Capital Growth	42.07%	29.36%	30.53%	24.02%	8.81%	31.24%	17.40%	34.26%	12.72%	13.76%
Revenue Q/Q Growth	7.77%	2.72%	6.45%	-19.16%	29.68%	7.05%	18.67%	-11.21%	0.15%	2.56%
EBITDA Q/Q Growth	5.54%	7.77%	11.01%	5.04%	9.18%	9.33%	15.41%	-17.94%	-3.36%	-3.34%
EBIT Q/Q Growth	5.11%	7.91%	11.52%	5.00%	9.48%	9.73%	15.77%	-19.29%	-3.96%	-3.92%
NOPAT Q/Q Growth	9.28%	12.45%	-7.29%	39.38%	-11.70%	17.71%	19.23%	-23.67%	-1.02%	-1.01%
Net Income Q/Q Growth	11.36%	12.30%	-6.23%	35.98%	-1.32%	11.32%	15.44%	-19.21%	-0.94%	-5.20%
EPS Q/Q Growth	11.29%	11.59%	-5.74%	35.86%	-1.12%	11.55%	15.19%	-19.23%	-0.77%	-5.17%
Operating Cash Flow Q/Q Growth	6.71%	7.88%	15.62%	7.96%	2.47%	20.40%	19.22%	-11.51%	-12.06%	4.08%
Free Cash Flow Firm Q/Q Growth	-142.44%	-65.54%	161.21%	15.51%	2.07%	-10.61%	33.76%	-35.99%	-21.96%	4.19%
Invested Capital Q/Q Growth	10.67%	31.34%	-2.37%	8.67%	2.03%	12.83%	5.08%	-1.06%	4.36%	2.93%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	90.43%	93.83%	93.24%	91.89%	88.33%	86.82%	84.83%	87.18%	86.16%	86.13%
EBITDA Margin	32.03%	29.64%	38.30%	53.05%	40.71%	48.29%	60.16%	43.21%	35.78%	37.45%
Operating Margin	30.51%	27.38%	35.41%	49.25%	33.70%	42.09%	55.67%	38.93%	30.85%	28.10%
EBIT Margin	30.20%	27.49%	35.82%	50.17%	37.50%	45.51%	58.38%	40.40%	32.57%	34.05%
Profit (Net Income) Margin	15.50%	18.42%	20.41%	47.50%	32.26%	41.35%	50.25%	35.64%	30.14%	31.07%
Tax Burden Percent	51.92%	67.34%	57.66%	95.73%	87.10%	92.20%	86.59%	89.29%	94.15%	92.32%
Interest Burden Percent	98.85%	99.53%	98.81%	98.91%	98.77%	98.53%	99.39%	98.79%	98.29%	98.86%
Effective Tax Rate	48.08%	32.66%	42.34%	4.27%	12.90%	7.80%	13.41%	10.71%	5.85%	7.68%
Return on Invested Capital (ROIC)	32.60%	33.39%	34.36%	54.81%	37.62%	53.49%	101.84%	43.97%	32.48%	27.72%
ROIC Less NNEP Spread (ROIC-NNEP)	33.86%	33.43%	34.40%	54.21%	33.64%	49.08%	97.34%	43.00%	31.34%	22.65%
Return on Net Nonoperating Assets (RNNOA)	-12.10%	-11.29%	-11.74%	-22.00%	-16.30%	-21.71%	-47.63%	-23.03%	-16.22%	-11.77%
Return on Equity (ROE)	20.50%	22.10%	22.63%	32.81%	21.32%	31.77%	54.21%	20.94%	16.26%	15.95%
Cash Return on Invested Capital (CROIC)	-2.16%	7.79%	7.88%	33.36%	29.18%	26.47%	85.83%	14.72%	20.51%	14.85%
Operating Return on Assets (OROA)	26.24%	21.24%	26.73%	25.19%	18.53%	24.19%	44.05%	18.00%	13.72%	13.65%
Return on Assets (ROA)	13.47%	14.23%	15.23%	23.85%	15.94%	21.98%	37.91%	15.88%	12.69%	12.46%
Return on Common Equity (ROCE)	20.50%	22.10%	22.63%	32.81%	21.32%	31.77%	54.21%	20.94%	16.26%	15.95%
Return on Equity Simple (ROE_SIMPLE)	17.40%	20.13%	19.51%	27.91%	19.08%	31.86%	43.03%	19.14%	15.22%	15.03%
Net Operating Profit after Tax (NOPAT)	650	896	1,199	2,426	1,925	3,298	7,747	4,231	3,810	3,684
NOPAT Margin	15.84%	18.44%	20.42%	47.15%	29.35%	38.81%	48.20%	34.76%	29.05%	25.94%
Net Nonoperating Expense Percent (NNEP)	-1.26%	-0.04%	-0.04%	0.60%	3.97%	4.41%	4.50%	0.97%	1.14%	5.07%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	16.68%	13.29%	11.49%
Cost of Revenue to Revenue	9.57%	6.17%	6.76%	8.11%	11.67%	13.18%	15.17%	12.82%	13.84%	13.87%
SG&A Expenses to Revenue	20.43%	24.23%	22.49%	21.91%	20.46%	15.84%	11.35%	17.38%	20.06%	20.80%
R&D to Revenue	39.49%	42.22%	35.34%	28.54%	37.36%	32.19%	18.09%	31.61%	35.26%	36.85%
Operating Expenses to Revenue	59.92%	66.46%	57.82%	42.63%	54.63%	44.73%	29.17%	48.25%	55.30%	58.03%
Earnings before Interest and Taxes (EBIT)	1,239	1,336	2,104	2,582	2,459	3,867	9,383	4,918	4,272	4,835
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,314	1,441	2,249	2,730	2,670	4,103	9,669	5,260	4,693	5,318
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	15.46	8.70	6.57	4.62	3.72	4.68	3.62	3.47	3.68	2.67
Price to Tangible Book Value (P/TBV)	15.46	8.70	6.57	4.62	3.72	4.68	3.62	3.61	3.84	2.78
Price to Revenue (P/Rev)	13.77	7.97	6.88	7.86	6.29	6.07	4.23	6.45	7.29	5.51
Price to Earnings (P/E)	88.82	43.24	33.70	16.54	19.48	14.67	8.41	18.11	24.20	17.74
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.13%	2.31%	2.97%	6.05%	5.13%	6.82%	11.89%	5.52%	4.13%	5.64%
Enterprise Value to Invested Capital (EV/IC)	23.58	12.32	9.67	7.46	6.65	6.79	6.98	6.07	6.61	4.46
Enterprise Value to Revenue (EV/Rev)	13.45	7.67	6.51	7.11	5.41	5.59	3.57	5.50	6.26	4.44
Enterprise Value to EBITDA (EV/EBITDA)	41.99	25.89	16.98	13.40	13.29	11.58	5.93	12.73	17.50	11.86
Enterprise Value to EBIT (EV/EBIT)	44.52	27.91	18.16	14.16	14.42	12.29	6.11	13.61	19.23	13.04
Enterprise Value to NOPAT (EV/NOPAT)	84.89	41.62	31.86	15.07	18.43	14.41	7.40	15.82	21.56	17.12
Enterprise Value to Operating Cash Flow (EV/OCF)	41.46	25.10	29.23	16.66	14.60	18.15	8.10	13.35	17.88	14.27
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	178.40	138.93	24.76	23.75	29.12	8.79	47.27	34.13	31.96
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.10	0.11	0.11	0.08	0.06	0.24	0.11	0.12	0.10	0.09
Long-Term Debt to Equity	0.10	0.08	0.11	0.08	0.06	0.24	0.11	0.12	0.10	0.09
Financial Leverage	-0.36	-0.34	-0.34	-0.41	-0.48	-0.44	-0.49	-0.54	-0.52	-0.52
Leverage Ratio	1.52	1.55	1.49	1.38	1.34	1.45	1.43	1.32	1.28	1.28
Compound Leverage Factor	1.50	1.55	1.47	1.36	1.32	1.42	1.42	1.30	1.26	1.27
Debt to Total Capital	9.03%	9.76%	10.27%	7.48%	6.05%	19.65%	9.54%	10.65%	9.43%	8.44%
Short-Term Debt to Total Capital	0.00%	2.63%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	9.03%	7.13%	10.27%	7.48%	6.05%	19.65%	9.54%	10.65%	9.43%	8.44%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	90.97%	90.24%	89.73%	92.51%	93.95%	80.35%	90.46%	89.35%	90.57%	91.56%
Debt to EBITDA	0.28	0.33	0.31	0.26	0.27	0.66	0.20	0.51	0.58	0.51
Net Debt to EBITDA	-1.00	-0.99	-0.97	-1.41	-2.16	-0.98	-1.09	-2.21	-2.88	-2.86
Long-Term Debt to EBITDA	0.28	0.24	0.31	0.26	0.27	0.66	0.20	0.51	0.58	0.51
Debt to NOPAT	0.56	0.54	0.59	0.29	0.37	0.82	0.26	0.64	0.71	0.73
Net Debt to NOPAT	-2.02	-1.59	-1.83	-1.59	-2.99	-1.22	-1.36	-2.75	-3.55	-4.13
Long-Term Debt to NOPAT	0.56	0.39	0.59	0.29	0.37	0.82	0.26	0.64	0.71	0.73
Altman Z-Score	19.47	11.22	11.62	10.45	8.80	7.66	9.48	9.81	10.64	8.03
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.59	2.56	3.82	4.47	3.67	3.63	3.56	5.06	5.69	4.73
Quick Ratio	3.10	2.13	2.98	3.50	2.86	2.86	2.98	4.16	4.82	3.86
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-43	209	275	1,477	1,493	1,632	6,529	1,416	2,407	1,973
Operating Cash Flow to CapEx	196.30%	290.27%	479.49%	572.98%	565.64%	425.98%	1,283.08%	849.84%	639.30%	600.77%
Free Cash Flow to Firm to Interest Expense	0.00	29.03	10.95	52.37	49.44	28.68	113.95	23.84	32.97	35.75
Operating Cash Flow to Interest Expense	0.00	206.38	52.08	77.84	80.46	46.01	123.58	84.43	62.93	80.08
Operating Cash Flow Less CapEx to Interest Expense	0.00	135.28	41.22	64.26	66.24	35.21	113.95	74.49	53.09	66.75
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.87	0.77	0.75	0.50	0.49	0.53	0.75	0.45	0.42	0.40
Accounts Receivable Turnover	3.36	3.16	3.28	2.44	2.61	2.46	3.17	2.14	2.39	2.39
Inventory Turnover	2.14	0.94	0.71	0.44	0.60	0.67	1.26	0.72	0.73	0.70
Fixed Asset Turnover	3.20	2.64	2.64	2.09	0.00	0.00	0.00	3.36	3.32	3.25
Accounts Payable Turnover	0.70	0.39	0.75	2.11	2.40	2.51	4.69	2.71	3.04	2.82
Days Sales Outstanding (DSO)	108.70	115.63	111.45	149.58	139.95	148.20	115.27	170.39	152.99	152.65
Days Inventory Outstanding (DIO)	170.76	388.47	517.24	820.62	612.24	543.00	289.60	509.14	500.76	524.93
Days Payable Outstanding (DPO)	524.02	927.55	485.91	173.28	151.78	145.62	77.83	134.88	120.19	129.30
Cash Conversion Cycle (CCC)	-244.57	-423.45	142.77	796.92	600.41	545.58	327.04	544.65	533.57	548.28
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,340	3,027	3,952	4,901	5,333	6,998	8,216	11,031	12,435	14,145
Invested Capital Turnover	2.06	1.81	1.68	1.16	1.28	1.38	2.11	1.26	1.12	1.07
Increase / (Decrease) in Invested Capital	693	687	924	949	432	1,666	1,218	2,815	1,403	1,711
Enterprise Value (EV)	55,179	37,295	38,200	36,569	35,469	47,524	57,363	66,939	82,149	63,069
Market Capitalization	56,494	38,717	40,393	40,426	41,226	51,551	67,916	78,572	95,687	78,278
Book Value per Share	$35.12	$42.18	$57.19	$80.91	$101.00	$103.32	$174.52	$208.11	$238.40	$267.12
Tangible Book Value per Share	$35.12	$42.18	$57.19	$80.91	$101.00	$103.32	$174.46	$199.71	$228.87	$256.67
Total Capital	4,018	4,930	6,848	9,466	11,804	13,721	20,749	25,366	28,676	32,058
Total Debt	363	481	704	709	714	2,696	1,980	2,701	2,703	2,704
Total Long-Term Debt	363	352	704	709	714	2,696	1,980	2,701	2,703	2,704
Net Debt	-1,314	-1,422	-2,193	-3,856	-5,757	-4,027	-10,553	-11,633	-13,538	-15,208
Capital Expenditures (CapEx)	678	512	273	383	430	615	552	590	719	736
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1,059	1,030	1,790	2,195	2,378	3,495	4,388	5,001	5,211	5,704
Debt-free Net Working Capital (DFNWC)	2,104	2,068	3,200	5,005	5,593	7,082	10,082	12,743	16,056	14,717
Net Working Capital (NWC)	2,104	1,939	3,200	5,005	5,593	7,082	10,082	12,743	16,056	14,717
Net Nonoperating Expense (NNE)	14	0.61	0.63	-18	-191	-216	-328	-107	-143	-729
Net Nonoperating Obligations (NNO)	-1,314	-1,422	-2,193	-3,856	-5,757	-4,027	-10,553	-11,633	-13,538	-15,208
Total Depreciation and Amortization (D&A)	75	105	146	148	210	236	286	341	421	483
Debt-free, Cash-free Net Working Capital to Revenue	25.80%	21.18%	30.48%	42.66%	36.27%	41.13%	27.30%	41.08%	39.73%	40.16%
Debt-free Net Working Capital to Revenue	51.27%	42.55%	54.49%	97.26%	85.28%	83.34%	62.73%	104.68%	122.40%	103.62%
Net Working Capital to Revenue	51.27%	39.89%	54.49%	97.26%	85.28%	83.34%	62.73%	104.68%	122.40%	103.62%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$6.17	$8.55	$11.27	$22.65	$19.38	$32.65	$76.40	$40.51	$37.05	$40.90
Adjusted Weighted Average Basic Shares Outstanding	103.06M	104.72M	106.34M	107.90M	109.20M	107.60M	105.70M	107.10M	106.70M	107.90M
Adjusted Diluted Earnings per Share	$5.52	$7.70	$10.34	$21.29	$18.46	$30.52	$71.97	$38.22	$34.77	$38.34
Adjusted Weighted Average Diluted Shares Outstanding	115.23M	116.37M	115.95M	114.80M	114.60M	115.10M	112.20M	113.50M	113.70M	115.10M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$19.38	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	104.79M	106.08M	107.70M	109.28M	110.02M	107.13M	108.54M	109.33M	109.76M	109.32M
Normalized Net Operating Profit after Tax (NOPAT)	650	896	1,199	2,426	1,925	3,298	7,747	4,231	3,810	3,684
Normalized NOPAT Margin	15.84%	18.44%	20.42%	47.15%	29.35%	38.81%	48.20%	34.76%	29.05%	25.94%
Pre Tax Income Margin	29.85%	27.36%	35.40%	49.62%	37.04%	44.84%	58.03%	39.91%	32.01%	33.66%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	185.57	83.81	91.55	81.43	67.97	163.75	82.80	58.52	87.59
NOPAT to Interest Expense	0.00	124.46	47.77	86.03	63.73	57.95	135.20	71.23	52.20	66.74
EBIT Less CapEx to Interest Expense	0.00	114.47	72.95	77.96	67.21	57.17	154.12	72.86	48.68	74.26
NOPAT Less CapEx to Interest Expense	0.00	53.36	36.91	72.45	49.51	47.15	125.57	61.30	42.35	53.41
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	90.16%	71.85%	0.00%	0.18%	13.04%	166.42%	20.38%	48.01%	56.53%	59.00%

This table displays calculated financial ratios and metrics derived from Regeneron Pharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-14.96%	-31.05%	6.64%	10.53%	14.53%	0.58%	-0.54%	12.32%	10.65%	10.33%
EBITDA Growth	-15.04%	-44.36%	-15.10%	14.68%	-23.72%	-11.32%	-14.82%	46.37%	31.97%	-14.38%
EBIT Growth	-16.70%	-46.69%	-18.49%	12.85%	-26.00%	-13.13%	-18.17%	49.11%	33.51%	-16.92%
NOPAT Growth	-35.75%	-55.91%	-21.85%	-7.42%	-5.48%	-5.14%	-14.20%	3.51%	5.07%	-3.52%
Net Income Growth	-19.39%	-46.29%	-15.99%	13.65%	-23.40%	-3.13%	-11.71%	47.90%	33.02%	-20.86%
EPS Growth	-18.63%	-46.48%	-16.72%	13.79%	-23.76%	-2.58%	-12.55%	46.00%	29.81%	-20.47%
Operating Cash Flow Growth	-81.58%	-27.51%	-34.93%	81.15%	77.18%	-36.64%	10.60%	-65.38%	15.88%	15.89%
Free Cash Flow Firm Growth	-5,270.86%	-257.05%	-328.23%	-232.02%	110.72%	76.37%	85.95%	15.49%	-416.67%	-81.35%
Invested Capital Growth	42.60%	34.26%	31.72%	21.89%	6.86%	12.72%	9.18%	16.68%	15.34%	13.76%
Revenue Q/Q Growth	2.76%	16.29%	-7.39%	-0.13%	6.48%	2.13%	-8.42%	12.79%	4.89%	1.84%
EBITDA Q/Q Growth	53.96%	-10.85%	-32.36%	23.52%	2.42%	3.64%	-35.03%	112.25%	-7.66%	-32.76%
EBIT Q/Q Growth	56.21%	-12.00%	-34.73%	25.78%	2.43%	3.31%	-38.52%	129.20%	-8.28%	-35.72%
NOPAT Q/Q Growth	8.61%	-2.82%	-12.93%	0.74%	10.89%	-2.47%	-21.24%	21.53%	12.55%	-10.45%
Net Income Q/Q Growth	54.41%	-9.01%	-31.68%	18.42%	4.07%	15.06%	-37.74%	98.38%	-6.40%	-31.55%
EPS Q/Q Growth	56.09%	-10.12%	-31.58%	18.55%	4.59%	14.85%	-38.59%	97.93%	-7.01%	-29.64%
Operating Cash Flow Q/Q Growth	11.43%	173.48%	-20.48%	-25.24%	8.99%	-2.21%	38.80%	-76.60%	264.75%	-2.20%
Free Cash Flow Firm Q/Q Growth	-359.97%	21.45%	-0.51%	35.68%	121.10%	-273.20%	40.25%	-286.94%	20.92%	0.81%
Invested Capital Q/Q Growth	18.53%	-1.06%	1.26%	2.64%	3.92%	4.36%	-1.92%	9.69%	2.72%	2.93%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	89.18%	84.17%	85.53%	87.18%	87.02%	84.95%	86.21%	86.46%	86.80%	85.08%
EBITDA Margin	55.10%	42.24%	30.85%	38.15%	36.70%	37.24%	26.42%	49.72%	43.77%	28.90%
Operating Margin	41.68%	33.59%	29.94%	32.19%	33.04%	28.33%	23.89%	30.15%	31.70%	26.13%
EBIT Margin	51.94%	39.31%	27.70%	34.89%	33.56%	33.95%	22.79%	46.32%	40.50%	25.56%
Profit (Net Income) Margin	44.81%	35.06%	25.86%	30.66%	29.97%	33.77%	22.96%	40.38%	36.03%	24.22%
Tax Burden Percent	87.14%	90.37%	95.31%	89.43%	90.73%	101.05%	103.04%	87.97%	89.79%	95.78%
Interest Burden Percent	99.00%	98.70%	97.95%	98.28%	98.42%	98.43%	97.75%	99.10%	99.08%	98.92%
Effective Tax Rate	12.86%	9.63%	4.69%	10.57%	9.27%	-1.05%	-3.04%	12.03%	10.21%	4.22%
Return on Invested Capital (ROIC)	52.50%	38.39%	35.93%	34.95%	34.04%	32.00%	27.60%	28.81%	30.72%	26.75%
ROIC Less NNEP Spread (ROIC-NNEP)	49.97%	36.94%	36.64%	34.45%	34.04%	30.60%	27.99%	25.22%	28.75%	26.96%
Return on Net Nonoperating Assets (RNNOA)	-25.48%	-19.78%	-20.05%	-18.37%	-17.10%	-15.84%	-15.03%	-13.22%	-15.15%	-14.01%
Return on Equity (ROE)	27.02%	18.61%	15.87%	16.58%	16.94%	16.17%	12.57%	15.59%	15.57%	12.74%
Cash Return on Invested Capital (CROIC)	23.33%	14.72%	13.10%	17.65%	26.74%	20.51%	22.69%	14.22%	14.76%	14.85%
Operating Return on Assets (OROA)	27.74%	17.51%	12.15%	15.28%	14.69%	14.30%	9.27%	18.72%	16.11%	10.25%
Return on Assets (ROA)	23.93%	15.62%	11.34%	13.43%	13.12%	14.22%	9.34%	16.32%	14.34%	9.71%
Return on Common Equity (ROCE)	27.02%	18.61%	15.87%	16.58%	16.94%	16.17%	12.57%	15.59%	15.57%	12.74%
Return on Equity Simple (ROE_SIMPLE)	25.05%	0.00%	17.80%	17.90%	16.03%	0.00%	14.29%	15.32%	15.87%	0.00%
Net Operating Profit after Tax (NOPAT)	1,066	1,036	902	909	1,008	983	774	941	1,059	948
NOPAT Margin	36.32%	30.35%	28.54%	28.78%	29.98%	28.63%	24.62%	26.53%	28.47%	25.03%
Net Nonoperating Expense Percent (NNEP)	2.53%	1.45%	-0.71%	0.50%	0.00%	1.40%	-0.39%	3.59%	1.97%	-0.21%
Return On Investment Capital (ROIC_SIMPLE)	-	4.09%	-	-	-	3.43%	-	-	-	2.96%
Cost of Revenue to Revenue	10.82%	15.83%	14.47%	12.82%	12.98%	15.05%	13.79%	13.54%	13.20%	14.92%
SG&A Expenses to Revenue	18.02%	19.34%	19.01%	20.65%	19.05%	21.48%	21.91%	21.39%	19.20%	20.91%
R&D to Revenue	31.04%	31.43%	36.60%	34.37%	34.95%	35.15%	39.92%	34.50%	35.68%	37.63%
Operating Expenses to Revenue	47.50%	50.58%	55.59%	54.99%	53.98%	56.62%	62.31%	56.31%	55.10%	58.95%
Earnings before Interest and Taxes (EBIT)	1,525	1,342	876	1,102	1,129	1,166	717	1,643	1,507	969
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	1,618	1,442	976	1,205	1,234	1,279	831	1,764	1,629	1,095
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.50	3.47	3.82	3.28	3.59	3.68	3.89	4.11	3.95	2.67
Price to Tangible Book Value (P/TBV)	3.64	3.61	3.98	3.42	3.74	3.84	4.04	4.27	4.11	2.78
Price to Revenue (P/Rev)	5.48	6.45	7.26	6.22	6.82	7.29	8.00	8.59	8.37	5.51
Price to Earnings (P/E)	13.98	18.11	21.48	18.34	22.38	24.20	27.18	26.80	24.90	17.74
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	7.15%	5.52%	4.66%	5.45%	4.47%	4.13%	3.68%	3.73%	4.02%	5.64%
Enterprise Value to Invested Capital (EV/IC)	5.81	6.07	6.94	5.78	6.41	6.61	7.38	7.55	7.30	4.46
Enterprise Value to Revenue (EV/Rev)	4.73	5.50	6.27	5.23	5.83	6.26	6.88	7.49	7.24	4.44
Enterprise Value to EBITDA (EV/EBITDA)	10.11	12.73	15.24	12.65	15.72	17.50	19.80	19.77	18.23	11.86
Enterprise Value to EBIT (EV/EBIT)	10.63	13.61	16.42	13.68	17.16	19.23	21.90	21.70	19.93	13.04
Enterprise Value to NOPAT (EV/NOPAT)	11.69	15.82	19.49	16.99	19.83	21.56	24.50	27.45	26.95	17.12
Enterprise Value to Operating Cash Flow (EV/OCF)	11.43	13.35	18.11	13.99	14.61	17.88	19.01	24.81	23.61	14.27
Enterprise Value to Free Cash Flow (EV/FCFF)	29.29	47.27	60.22	35.97	24.76	34.13	33.98	57.18	52.96	31.96
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.13	0.12	0.12	0.11	0.11	0.10	0.10	0.10	0.09	0.09
Long-Term Debt to Equity	0.13	0.12	0.12	0.11	0.11	0.10	0.10	0.10	0.09	0.09
Financial Leverage	-0.51	-0.54	-0.55	-0.53	-0.50	-0.52	-0.54	-0.52	-0.53	-0.52
Leverage Ratio	1.33	1.32	1.30	1.29	1.29	1.28	1.28	1.28	1.28	1.28
Compound Leverage Factor	1.31	1.30	1.27	1.27	1.27	1.26	1.25	1.27	1.27	1.27
Debt to Total Capital	11.19%	10.65%	10.31%	10.11%	9.79%	9.43%	9.10%	8.75%	8.44%	8.44%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	11.19%	10.65%	10.31%	10.11%	9.79%	9.43%	9.10%	8.75%	8.44%	8.44%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	88.81%	89.35%	89.69%	89.89%	90.21%	90.57%	90.90%	91.25%	91.56%	91.56%
Debt to EBITDA	0.42	0.51	0.53	0.52	0.56	0.58	0.59	0.53	0.49	0.51
Net Debt to EBITDA	-1.61	-2.21	-2.42	-2.40	-2.67	-2.88	-3.25	-2.90	-2.83	-2.86
Long-Term Debt to EBITDA	0.42	0.51	0.53	0.52	0.56	0.58	0.59	0.53	0.49	0.51
Debt to NOPAT	0.49	0.64	0.68	0.69	0.70	0.71	0.74	0.73	0.73	0.73
Net Debt to NOPAT	-1.86	-2.75	-3.10	-3.22	-3.37	-3.55	-4.02	-4.03	-4.19	-4.13
Long-Term Debt to NOPAT	0.49	0.64	0.68	0.69	0.70	0.71	0.74	0.73	0.73	0.73
Altman Z-Score	9.56	9.41	10.39	9.34	9.60	10.33	10.65	11.00	10.72	7.69
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.36	5.06	5.45	5.45	5.18	5.69	5.27	5.44	5.28	4.73
Quick Ratio	4.37	4.16	4.54	4.53	4.31	4.82	4.40	4.43	4.34	3.86
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-2,265	-1,779	-1,788	-1,150	243	-420	-251	-972	-768	-762
Operating Cash Flow to CapEx	441.33%	1,130.03%	767.45%	904.78%	633.13%	433.45%	1,129.57%	196.12%	533.77%	632.67%
Free Cash Flow to Firm to Interest Expense	-148.01	-102.23	-99.33	-60.85	13.63	-22.97	-15.60	-65.66	-55.69	-72.60
Operating Cash Flow to Interest Expense	41.10	98.84	75.98	54.10	62.60	59.55	93.94	23.92	93.57	120.27
Operating Cash Flow Less CapEx to Interest Expense	31.79	90.10	66.08	48.12	52.71	45.81	85.63	11.72	76.04	101.26
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.53	0.45	0.44	0.44	0.44	0.42	0.41	0.40	0.40	0.40
Accounts Receivable Turnover	2.49	2.14	2.48	2.46	2.35	2.39	2.53	2.49	2.37	2.39
Inventory Turnover	0.90	0.72	0.73	0.73	0.74	0.73	0.70	0.69	0.69	0.70
Fixed Asset Turnover	3.86	3.36	3.33	3.35	3.40	3.32	3.23	3.28	3.28	3.25
Accounts Payable Turnover	4.16	2.71	3.02	3.18	3.43	3.04	2.82	3.37	3.72	2.82
Days Sales Outstanding (DSO)	146.43	170.39	146.91	148.10	155.13	152.99	144.06	146.64	154.09	152.65
Days Inventory Outstanding (DIO)	407.03	509.14	499.66	501.24	493.53	500.76	523.40	525.91	529.81	524.93
Days Payable Outstanding (DPO)	87.73	134.88	121.04	114.70	106.38	120.19	129.41	108.38	98.17	129.30
Cash Conversion Cycle (CCC)	465.73	544.65	525.53	534.64	542.27	533.57	538.04	564.17	585.74	548.28
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	11,150	11,031	11,171	11,465	11,915	12,435	12,196	13,378	13,743	14,145
Invested Capital Turnover	1.45	1.26	1.26	1.21	1.14	1.12	1.12	1.09	1.08	1.07
Increase / (Decrease) in Invested Capital	3,331	2,815	2,690	2,059	765	1,403	1,025	1,913	1,828	1,711
Enterprise Value (EV)	64,803	66,939	77,505	66,279	76,350	82,149	90,065	100,980	100,300	63,069
Market Capitalization	75,093	78,572	89,830	78,831	89,339	95,687	104,860	115,808	115,883	78,278
Book Value per Share	$196.67	$208.11	$214.91	$218.92	$229.41	$238.40	$250.38	$255.98	$266.03	$267.12
Tangible Book Value per Share	$189.29	$199.71	$206.42	$210.23	$220.04	$228.87	$240.56	$245.98	$255.87	$256.67
Total Capital	24,140	25,366	26,197	26,720	27,607	28,676	29,695	30,910	32,030	32,058
Total Debt	2,701	2,701	2,702	2,702	2,703	2,703	2,703	2,704	2,704	2,704
Total Long-Term Debt	2,701	2,701	2,702	2,702	2,703	2,703	2,703	2,704	2,704	2,704
Net Debt	-10,289	-11,633	-12,325	-12,553	-12,990	-13,538	-14,795	-14,828	-15,583	-15,208
Capital Expenditures (CapEx)	143	152	178	113	176	251	134	181	242	200
Debt-free, Cash-free Net Working Capital (DFCFNWC)	5,528	5,001	4,849	4,891	5,123	5,211	4,771	5,764	5,876	5,704
Debt-free Net Working Capital (DFNWC)	12,549	12,743	13,809	13,819	15,036	16,056	15,291	15,573	15,673	14,717
Net Working Capital (NWC)	12,549	12,743	13,809	13,819	15,036	16,056	15,291	15,573	15,673	14,717
Net Nonoperating Expense (NNE)	-249	-161	85	-59	0.18	-177	52	-491	-281	31
Net Nonoperating Obligations (NNO)	-10,289	-11,633	-12,325	-12,553	-12,990	-13,538	-14,795	-14,828	-15,584	-15,208
Total Depreciation and Amortization (D&A)	93	100	100	103	105	113	114	121	122	126
Debt-free, Cash-free Net Working Capital to Revenue	40.32%	41.08%	39.20%	38.60%	39.11%	39.73%	36.42%	42.73%	42.44%	40.16%
Debt-free Net Working Capital to Revenue	91.53%	104.68%	111.63%	109.06%	114.80%	122.40%	116.72%	115.45%	113.18%	103.62%
Net Working Capital to Revenue	91.53%	104.68%	111.63%	109.06%	114.80%	122.40%	116.72%	115.45%	113.18%	103.62%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$12.31	$11.18	$7.64	$9.05	$9.48	$10.88	$6.70	$13.25	$12.40	$8.55
Adjusted Weighted Average Basic Shares Outstanding	106.90M	107.10M	107.10M	107M	106.30M	106.70M	107.80M	108.10M	108.10M	107.90M
Adjusted Diluted Earnings per Share	$11.66	$10.48	$7.17	$8.50	$8.89	$10.21	$6.27	$12.41	$11.54	$8.12
Adjusted Weighted Average Diluted Shares Outstanding	112.80M	113.50M	114M	113.90M	113.40M	113.70M	115.10M	115.40M	116.20M	115.10M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	108.90M	109.33M	109.71M	108.56M	108.95M	109.76M	110.19M	110.23M	109.89M	109.32M
Normalized Net Operating Profit after Tax (NOPAT)	1,066	1,036	902	909	1,008	681	526	941	1,059	948
Normalized NOPAT Margin	36.32%	30.35%	28.54%	28.78%	29.98%	19.83%	16.72%	26.53%	28.47%	25.03%
Pre Tax Income Margin	51.42%	38.80%	27.13%	34.29%	33.03%	33.42%	22.28%	45.90%	40.13%	25.29%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	99.68	77.13	48.67	58.30	63.40	63.71	44.52	111.01	109.19	92.25
NOPAT to Interest Expense	69.70	59.56	50.13	48.10	56.63	53.72	48.09	63.58	76.75	90.33
EBIT Less CapEx to Interest Expense	90.37	68.39	38.77	52.32	53.52	49.97	36.21	98.81	91.66	73.24
NOPAT Less CapEx to Interest Expense	60.38	50.81	40.23	42.12	46.74	39.98	39.77	51.38	59.22	71.32
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	46.90%	48.01%	58.23%	64.32%	59.56%	56.53%	47.06%	40.05%	41.24%	59.00%

Frequently Asked Questions About Regeneron Pharmaceuticals' Financials

When does Regeneron Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Regeneron Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Regeneron Pharmaceuticals' net income changed over the last 9 years?

Regeneron Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $4.41 billion in 2024, rising from $636.06 million in 2015. The previous period was $3.95 billion in 2023.

What is Regeneron Pharmaceuticals's operating income?

Regeneron Pharmaceuticals's total operating income in 2024 was $3.99 billion, based on the following breakdown:

Total Gross Profit: $12.23 billion
Total Operating Expenses: $8.24 billion

How has Regeneron Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Regeneron Pharmaceuticals' total revenue changed from $4.10 billion in 2015 to $14.20 billion in 2024, a change of 246.1%.

How much debt does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals' total liabilities were at $8.41 billion at the end of 2024, a 18.3% increase from 2023, and a 330.1% increase since 2015.

How much cash does Regeneron Pharmaceuticals have?

In the past 9 years, Regeneron Pharmaceuticals' cash and equivalents has ranged from $535.20 million in 2016 to $3.11 billion in 2022, and is currently $2.49 billion as of their latest financial filing in 2024.

How has Regeneron Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Regeneron Pharmaceuticals' book value per share changed from 35.12 in 2015 to 267.12 in 2024, a change of 660.6%.

Remove Ads

Related Companies

This page (NASDAQ:REGN) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Regeneron Pharmaceuticals (REGN) Financials

Frequently Asked Questions About Regeneron Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Regeneron Pharmaceuticals (REGN) Financials

Annual Income Statements for Regeneron Pharmaceuticals

Quarterly Income Statements for Regeneron Pharmaceuticals

Annual Cash Flow Statements for Regeneron Pharmaceuticals

Quarterly Cash Flow Statements for Regeneron Pharmaceuticals

Annual Balance Sheets for Regeneron Pharmaceuticals

Quarterly Balance Sheets for Regeneron Pharmaceuticals

Annual Metrics and Ratios for Regeneron Pharmaceuticals

Quarterly Metrics and Ratios for Regeneron Pharmaceuticals

Frequently Asked Questions About Regeneron Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools